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Studies of prevalence and the demographic profile of type 1 diabetes are challenging because of the
relative rarity of the condition, however, these outcomes can be determined using routine healthcare
data repositories. Understanding the epidemiology of type 1 diabetes allows for targeted interventions
and care of this life-affecting condition.
Objectives
To describe the prevalence, incidence and demographics of persons with type 1 diabetes diagnosed
in Wales, UK, using the Secure Anonymised Information Linkage (SAIL) Databank.
Methods
Data derived from primary and secondary care throughout Wales available in the SAIL Databank
were used to identify people with type 1 diabetes to determine the prevalence and incidence of type
1 diabetes over a 10 year period (2008–18) and describe the demographic and clinical characteristics
of this population by age, socioeconomic deprivation and settlement type. The seasonal variation in
incidence rates was also examined.
Results
The prevalence of type 1 diabetes in 2018 was 0.32% in the whole population, being greater in
men compared to women (0.35% vs 0.28% respectively); highest in those aged 15-29 years (0.52%)
and living in the most socioeconomically deprived areas (0.38%). The incidence of type 1 diabetes
over 10 years was 14.0 cases/100,000 people/year for the whole population of Wales. It was highest
in children aged 0-14 years (33.6 cases/100,000 people/year) and areas of high socioeconomic
deprivation (16.8 cases/100,000 people/year) and least in those aged 45-60 years (6.5 cases/100,000
people/year) and in areas of low socioeconomic deprivation (11.63 cases/100,000 people/year). A
seasonal trend in the diagnoses of type 1 diabetes was observed with higher incidence in winter
months.
Conclusion
This nation-wide retrospective epidemiological study using routine data revealed that the incidence
of type 1 diabetes in Wales was greatest in those aged 0-14 years with a higher incidence and
prevalence in the most deprived areas. These findings illustrate the need for health-related policies
targeted at high deprivation areas to include type 1 diabetes in their remit.
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Introduction
Type 1 diabetes mellitus results from an immune-mediated
destruction of the insulin-producing cells in the pancreas,
typically presenting with symptoms related to raised blood
glucose concentrations, including weight loss, excessive thirst
and urination and hunger with some cases presenting acutely
with the life-threatening metabolic disorder ketoacidosis which
may lead to coma and death. Type 1 diabetes requires life-
long treatment with exogenous insulin therapy accompanied
by blood glucose monitoring. The International Diabetes
Federation (IDF) reported in 2019 that over 1.1 million
children and young people had type 1 diabetes worldwide, with
129,000 new cases diagnosed each year [1]. In the UK during
2010–2011, the direct cost of caring for people with type 1
diabetes to the National Health Service was£1.0 billion, which
is expected to rise to £1.8 billion by 2035–2036. In addition,
indirect costs were estimated to be 0.9 billion in 2010–2011,
rising to £2.4 billion in 2035–2036 [2].
It is essential to have accurate data on the number of
people with type 1 diabetes in order to determine both
current and future health care resources required to maintain
the health of this highly vulnerable population who are at
significant risk of short and long-term complications. Although
type 1 diabetes may present at any age it is traditionally
regarded as a condition occurring predominantly in childhood,
which has been the main focus for the majority of studies
reporting prevalence and incidence of type 1 diabetes. These
studies have demonstrated that in some countries such as the
United States the incidence is rising [3], although in others
such as Finland [4], Western Australia [5] and Ireland [6] the
reported rate of increase has slowed or even stopped. Studies
examining the prevalence, incidence and rate of complications
of type 1 diabetes must reflect the fact that type 1 diabetes
can present at any age [7]. In the UK the Quality and
Outcomes Framework (QoF) combined with the National
Paediatric Diabetes Audit [8] provided a dataset which allowed
for the estimation of diabetes prevalence and incidence in the
entire population [9, 10] with the National Diabetes Audit
(NDA) providing an estimate of prevalence in adults [11].
Published reports from the NPDA have shown that in the
UK, the incidence of type 1 diabetes in children has remained
approximately constant in recent years. There are also local
audits available, for example the Brecon cohort, a register of
people with type 1 diabetes diagnosed under the age of 16
years in Wales [12]. The availability of large-scale research
databanks has made it possible to perform epidemiological
research without the need for specially gathered registry
data. This study builds upon previous work to develop
algorithms to identify incident cases of diabetes in the Clinical
Practice Research Datalink [13], the UK IMS disease analyser
[14], The Health Improvement Network [15], administrative
data from Ontario, Canada [16] and Luxembourg [17]
and in the Scottish Care Information-Diabetes Collaboration
[18]. These methods typically use coded diagnoses and/or
medication prescriptions and laboratory tests to identify
cases of diabetes, however, due to the anonymised nature
of these data sources and the inherent issues related
to routinely collected data, robust data cleaning methods
are required to ensure the accuracy of the cohort being
studied [19].
Previous work on incident cases of type 1 diabetes has
shown that more people are diagnosed in winter months than
summer months [27]. This effect appears to be due to periods
of cold weather as it persists in Southern hemisphere countries
[28] but its underlying cause is not well understood [29]. We
will test our cohort to see if we observe a seasonal variation in
incident cases.
This retrospective epidemiological study aimed to identify
all persons in Wales, diagnosed in both childhood and
adulthood, with type 1 diabetes using anonymised, routinely
collected healthcare data held in the Secure Anonymised
Information Linkage (SAIL) Databank and to compute
estimates of the true prevalence and incidence of type 1
diabetes in this population along with the demographic and
clinical characteristics.
Methods
Routine electronic health record data held in the SAIL
Databank [20–22] from multiple sources including both
primary and secondary care were used for this study.
Primary care sources include the Welsh Longitudinal General
Practice (WLGP) dataset which covered approximately 80%
of the population of Wales over the study period and
commenced in 2000, with coverage increasing over time.
The data included medications prescribed, laboratory test
results and coded diagnoses made by a general practitioner.
Inpatient and outpatient hospital records commenced in
1995, covered 100% of Wales and included dates of hospital
admissions, diagnoses made and procedures carried out.
Demographic and geographical information was drawn from
the Welsh Demographic Service (WDS) dataset, which
contains administrative data on all persons registered with a
primary care practice in Wales. Any event, admission or service
received before the index date, which was June 1st 2018, was
included in the study.
People commonly have multiple coded diagnoses of
diabetes recorded in the routine data which may or may not
specify a particular type of diabetes. Therefore the following
criteria were used to identify people with type 1 diabetes: those
with a majority of coded diagnoses of type 1 diabetes in both
hospitals and general practice, were assigned a diagnosis of
type 1 diabetes if insulin was prescribed within 12 months of
the earliest recorded date of diagnosis of diabetes, if insulin
was prescribed at least 6 months prior to any oral antidiabetic
drug (OAD), if a hospital inpatient episode with a diagnosis of
diabetic ketoacidosis (DKA) was recorded, or medical devices
commonly used in the care of type 1 diabetes (blood glucose
monitors, glucose and ketone test strips) were prescribed on
at least 5 occasions within 6 months of diagnosis. People
who did not have a majority of coded diagnoses of type 1
diabetes were only assigned a diagnosis of type 1 diabetes
if insulin was prescribed within 6 months of the earliest
recorded date of diagnosis of diabetes and, if concomitant
OAD therapy was prescribed, at least six months after
insulin initiation. The only permissible OAD therapies were
metformin, sulphonylureas, glucagon-like peptide 1 (GLP-
1) agonists or sodium-glucose transport protein 2 (SGLT-2)
inhibitor agents. People presenting with type 1 diabetes before
2000 may not be identified by this algorithm since data on
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medication prescriptions were not generally available prior to
this date, although coded diagnosis data often is available.
For this reason, only new diagnoses of type 1 diabetes from
2008 onwards were used for incidence calculations. However,
prevalence calculations involved all people living with type 1
diabetes diagnosed at any time.
The date of diagnosis was either the first recorded diagnosis
of type 1 diabetes in any dataset, or the earliest recorded
prescription of insulin in the WLGP dataset, whichever was
earliest. All persons with a code for type 1 diabetes who
also had some other pancreatic condition such as cystic
fibrosis or pancreatic cancer prior to type 1 diabetes diagnosis
were excluded from the cohort. The complete list of relevant
diagnosis codes are included in Supplementary Tables 1 and 2.
Deprivation was assigned using the Welsh Index of Multiple
Deprivation 2011 (WIMD) score quintile. Each Lower layer
Super Output Area (LSOA), small geographic areas where the
minimum population is 1000 people and the mean population
is 1500 people, is assigned a WIMD score quantifying the
deprivation in that area [23]. Settlement type (rural, town and
urban areas, based on population density [24]) was also derived
from each LSOA.
The numbers of people identified with type 1 diabetes
over the whole period of data coverage was used to estimate
the prevalence and incidence of the condition on the index
date. The prevalence was calculated by dividing the number
of persons with type 1 diabetes living in Wales (including those
diagnosed outside Wales) and registered at a SAIL primary care
general practice by the total number of people registered at
a SAIL primary care general practice, both on the index date.
The incidence was calculated by dividing the number of people
newly diagnosed with type 1 diabetes in a calendar year while
registered at a SAIL primary care general practice and resident
in Wales by the total number of people registered at a SAIL
primary care general practice on the 1st June of each year.
Univariate Poisson regression was used to check for differences
between population subgroups with the null hypothesis being
that there was an equal probability of having type 1 diabetes in
each population subgroup. For each model, only the variable
under investigation (WIMD quintile, settlement type, month
of diagnosis) was included as the independent variable. The
dependent variable was the number of incident persons with
T1DM or the number of prevalent persons with T1DM. An
offset variable was included in each model to account for
the differences in population sizes in the different categories.
To evaluate the model fit we computed the ratio of the
residual deviance to the degrees of freedom, with a value less
than or greater than unity indicating under or over dispersion
respectively. Lack of under or over dispersion was taken to
imply standard error estimates were reasonable.
To illustrate the seasonal variation of newly-diagnosed
cases of type 1 diabetes in people under 18 years of age, we
took the number of newly-diagnosed cases of type 1 diabetes
in each calendar month in the ten years prior to the index date
and computed the mean for each month. To account for the
difference in the number of days in each month we further
divided each mean number by 12nmonth365.25 where nmonth is the
number of days in the month. Since there were two leap years
during the study period, we took the length of February as
28.2 days. Confidence intervals for prevalence and incidence
were computed using Jeffrey’s interval [25].
Results
Demographic characteristics of the population with type 1
diabetes living in Wales during the study period are represented
in Table 1. There were 7857 people with type 1 diabetes
diagnosed prior to the index date that had records in the
WLGP data (see Figure 1), giving an overall prevalence of
0.32% (95% CI 0.31, 0.32). More men (n= 4366) than women
(n= 3491) had type 1 diabetes, with a prevalence 0.35% (95%
CI 0.34, 0.36) and 0.28% (95% CI 0.27, 0.29) respectively.
47.3% of people with type 1 diabetes were diagnosed under
age 18, whereas 71.5% of the population with type 1 diabetes
were diagnosed under the age of 30 years. 95% of type 1
diabetes diagnoses occurred before age 53 (Table 1).
The prevalence of type 1 diabetes was highest in those
aged 15–29 years at 0.52% (95% CI 0.50, 0.55). The average
incidence in the 10 years prior to the index date was 14.0
cases/100,000 people/year (95% CI 12.5, 15.5), whereas the
age group with the highest incidence was those aged 0 to 14
years at 33.6 cases/100,000 people/year (95% CI 28.0, 39.6)
(Table 2).
The prevalence of type 1 diabetes was 31.0% higher in
the most socially deprived areas when compared to the least
deprived areas. Furthermore, all regions that had greater
deprivation than the least deprived areas had a higher
prevalence of type 1 diabetes. There was also a difference
in incidence rates only when comparing regions in the most
deprived and least deprived quintiles (p= 0.040) (Table 3).
The prevalence of type 1 diabetes was higher in urban areas
compared to rural areas, with a 14.2% difference. There was
no difference however in the observed incidence rates across
different settlement types (Table 4).
There was a seasonal trend in the rate of diagnosis of type 1
diabetes in children and young people which was highest during
February (p= 0.025) and lowest during the months of July
(p= 0.018) and August (p= 0.005) (Figure 2).
Discussion
We found that the prevalence of type 1 diabetes in people of
all ages in Wales was 0.32%. The only prior study we are aware
of that investigated type 1 diabetes prevalence in people of all
ages used QoF data and found the prevalence to be 0.4% in
Wales in 2014 [9, 10], which is slightly higher than our finding.
This discrepancy could arise from the criteria adopted in this
study which required that persons must have had a recorded
prescription of insulin within 12 months of the date they were
diagnosed.
The SAIL Databank was established in 2007 and contains
data going back to 2000 or earlier, with historic data prior to
that depending on the data source and quality of electronic
data capture. People diagnosed with type 1 diabetes before
2000 will be unlikely to have their early insulin prescriptions
recorded, so were not therefore included in our cohort. In 2015
Holman et al. found a prevalence of any diabetes in Wales of
0.2% when restricted to children and young people under the
age of 16 years [10].
Importantly, we discovered that the prevalence of type 1
diabetes was 31.0% higher, and the incidence 42% higher in
the most deprived areas compared to areas with the least
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Table 1: Demographic information
Statistic Value
N 7857
Men n (%) 4366 (55.6%)
Population age median (LQ, UQ) 34.5 (23.2, 50.3)
Diabetes duration median (LQ, UQ) 13.5 (6.4, 21.1)
Age at diagnosis median (LQ, UQ) 19.2 (10.6, 32.0)
Percentage diagnosed under 18 47.5%
Percentage diagnosed under 30 71.5%
Percentage diagnosed under 53 95%
Key: LQ - Lower quartile, UQ - Upper quartile.
Figure 1: Flow diagram detailing cohort construction
Table 2: The prevalence and incidence of type 1 diabetes by age group up to the age of 60. People with type 1 diabetes aged over
60 were included in the full cohort but not in this table as the numbers were small
Prevalence % Incidence/100,000
Age range (95% CI) people/year (95% CI)
0–14 0.18% (0.17, 0.20) 33.55 (28.02, 39.56)
15–29 0.52% (0.50, 0.55) 26.87 (22.32, 31.83)
30–44 0.45% (0.43, 0.47) 13.15 (10.02, 16.70)
45–60 0.33% (0.31, 0.35) 6.49 (4.39, 8.98)
Key: CI - Confidence interval.
deprivation. In contrast to our findings, a study in Finland
found a six fold higher incidence of type 1 diabetes in
children under 15 years in a population with a lower level of
socioeconomic deprivation [26]. Excessive cleanliness has been
hypothesised to explain the greater prevalence of autoimmune
conditions such as type 1 diabetes, due to reduced exposure
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Table 3: The prevalence and incidence of type 1 diabetes by Welsh Index of Multiple Deprivation (WIMD) quintile, with p-values
from a Poisson regression model. The 1st WIMD quintile represents the most deprived areas, whereas areas in the 5th quintile are
the least deprived
WIMD quintile Prevalence (%, 95% CI) p-value Incidence (/100,000, 95% CI) p-value
1 0.38 (0.36, 0.39) <0.001 16.80 (13.40, 20.59) 0.040
2 0.36 (0.34, 0.37) <0.001 14.85 (11.55, 18.56) 0.196
3 0.34 (0.32, 0.36) <0.001 14.24 (11.04, 17.84) 0.344
4 0.32 (0.30, 0.34) <0.001 12.01 (8.91, 15.57) 0.753
5 0.29 (0.27, 0.30) Reference 11.63 (8.79, 14.86) Reference
Key: CI - Confidence interval.
Table 4: The prevalence and incidence of type 1 diabetes by settlement type
Settlement type Prevalence (% 95% CI) p-value Incidence (/100,000, 95% CI) p-value
Rural 0.28 (0.26, 0.29) <0.001 14.45 (12.66, 16.36) 0.403
Town 0.32 (0.30, 0.34) <0.001 13.43 (9.99, 17.38) 0.589
Urban 0.31 (0.31, 0.32) Reference 12.27 (8.80, 16.30) Reference
Key: CI - Confidence interval.
Figure 2: The mean number of individuals under 18 years of age with newly-diagnosed (i.e. incident) type 1 diabetes per month in
each year of the study period. We have normalised the values by the number of days in the month, so that points are comparable
to infectious diseases which would otherwise enhance the
immune response. Deprivation defined by the WIMD criteria
which were used in this study does include quantification of
housing quality, air quality, air emissions and proximity to
waste and industrial sites but is not necessarily a good proxy
for the cleanliness of the exposed environment [23]. However,
comparing different measures of deprivation is problematic,
due to the use of different indicators to quantify deprivation.
The prevalence of type 1 diabetes was highest in urban areas
and it is likely these two observations are related, as settlement
type and deprivation quintile are highly correlated. These
findings illustrate the need for programmes aimed at areas of
highest deprivation to include type 1 diabetes in their remit.
There was a seasonal variation in the diagnosis of type
1 diabetes, with fewer diagnoses in July and August with
a peak during February. The size of the seasonal effect
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observed in this study is in broad agreement with centres of
comparable latitude as seen in a multicentre European study
[27]. The pattern of increased winter diagnoses persists in both
northern and southern hemispheres, but unfortunately there
are only a few studies reporting results from the southern
hemisphere [28]. Several causes for this seasonal variation
have been proposed including seasonal variations in infectious
disease, sun or average temperature exposure or patterns of
diet and exercise but currently the mechanism is not fully
understood [29].
There are some limitations to our study. Approximately
80% of people had their GP data available in the SAIL
Databank which are not always complete. Also routine
databanks only provide access to coded data so free text
records are not available for error checking or adjudication and
importantly, routine databanks only contain anonymised data
preventing follow up to resolve any queries. However, data
linkage is a growing field of study in medical research, and
new datasets that provide a more detailed picture of people
with type 1 diabetes are being added to the SAIL Databank
and other repositories on a regular basis. The method used in
this study to designate people with type 1 diabetes allowed
for a twelve month period from initial diagnosis to receiving a
first prescription for insulin in primary care to accommodate
for the time between diagnosis (usually in secondary care) and
medication prescriptions recorded in primary care. Information
on medication prescriptions in secondary care was not available
in the SAIL Databank for the purposes of this study. In
addition, those people misdiagnosed as having type 2 diabetes
and given oral medication prior to the correct diagnosis being
established and commencement of insulin therapy will be
excluded from the study cohort as not having type 1 diabetes
by our chosen algorithm. Also, if the person has type 2
diabetes but is misdiagnosed as type 1 diabetes and the
error is not rectified within 12 months, the algorithm would
erroneously identify them as having type 1 diabetes. Given
that our prevalence findings are broadly in agreement with
previous work on the subject it is likely any misclassification
error is small. Furthermore, misdiagnosing type 1 diabetes as
type 2 diabetes is relatively unlikely, and our lower estimate
of prevalence compared with the work of Holman et al.
[9, 10] suggests more false negatives than false positives.
People relocating into Wales and registering with a GP will
be considered a new diagnosis, which would result in a small
overestimate in the incidence of type 1 diabetes. Migration
within Wales however is correctly accounted for and does not
erroneously increase the incidence estimate.
This most recent epidemiological study of people with type
1 diabetes, based on defined diagnostic criteria, in a population
of all ages living in Wales has employed the resources of the
SAIL Databank, a repository of anonymised routine medical
data. This has made it possible to calculate the prevalence
and incidence of type 1 diabetes over the stated study period
and provide a description of the population being surveyed.
This study found that in Wales in 2018 the prevalence of type
1 diabetes was 0.32%, with a higher prevalence in men than
women (0.35% vs. 0.28%), highest in people aged 15–34 years
at 0.52% and higher in the most deprived areas at 0.38%. The
incidence of type 1 diabetes for children and young people
was higher in the winter months of January and February, and
lowest in the months of July and August. This study provides
important additional epidemiological and clinical information
about the status of type 1 diabetes in Wales with respect to
its prevalence and incidence in relationship to age, gender and
socioeconomic status. The findings provide essential evidence
to generate future health care policies better able to define
and target the needs of this vulnerable group and also
encourage the introduction of preventative strategies. This
study also forms the basis for future epidemiological studies
to monitor the impact of different interventions in clinical care
and socioeconomic factors especially the devastating influence
of deprivation in Wales. Lessons learnt from conducting
this study will result in more comprehensive and improved
future epidemiological studies which will be able to provide
more accurate estimates of the prevalence and incidence of
type 1 diabetes in Wales. Using similar methodology within
and between countries/regions will also allow more meaningful
comparisons to be made.
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READ_CD Description TYPE_NUM
C1000 Diabetes mellitus, juvenile type, with no mention of complication 1
C1010 Type 1 diabetes mellitus with ketoacidosis 1
C1020 Diabetes mellitus, juvenile type, with hyperosmolar coma 1
C1030 Type 1 diabetes mellitus with ketoacidotic coma 1
C1040 Diabetes mellitus, juvenile type, with renal manifestation 1
C1050 Diabetes mellitus, juvenile type, with ophthalmic manifestation 1
C1060 Diabetes mellitus, juvenile type, with neurological manifestation 1
C1070 Diabetes mellitus, juvenile type, with peripheral circulatory disorder 1
C1080 Type 1 diabetes mellitus with renal complications 1
C1082 Type I diabetes mellitus with neurological complications 1
C1085 Type 1 diabetes mellitus with ulcer 1
C1087 Type 1 diabetes mellitus with retinopathy 1
C1088 Type 1 diabetes mellitus - poor control 1
C1089 Type I diabetes mellitus maturity onset 1
C10E. Type 1 diabetes mellitus 1
C10E0 Type 1 diabetes mellitus with renal complications 1
C10E1 Type 1 diabetes mellitus with ophthalmic complications 1
C10E2 Type 1 diabetes mellitus with neurological complications 1
C10E3 Type 1 diabetes mellitus with multiple complications 1
C10E4 Unstable type 1 diabetes mellitus 1
C10E5 Type 1 diabetes mellitus with ulcer 1
C10E6 Type 1 diabetes mellitus with gangrene 1
C10E7 Type 1 diabetes mellitus with retinopathy 1
C10E8 Type 1 diabetes mellitus - poor control 1
C10E9 Type 1 diabetes mellitus maturity onset 1
C10EA Type 1 diabetes mellitus without complication 1
C10EB Type 1 diabetes mellitus with mononeuropathy 1
C10EC Type 1 diabetes mellitus with polyneuropathy 1
C10ED Type 1 diabetes mellitus with nephropathy 1
C10EE Type 1 diabetes mellitus with hypoglycaemic coma 1
C10EF Type 1 diabetes mellitus with diabetic cataract 1
C10EG Type 1 diabetes mellitus with peripheral angiopathy 1
C10EH Type 1 diabetes mellitus with arthropathy 1
C10EJ Type 1 diabetes mellitus with neuropathic arthropathy 1
C10EK Type 1 diabetes mellitus with persistent proteinuria 1
C10EL Type 1 diabetes mellitus with persistent microalbuminuria 1
C10EM Type 1 diabetes mellitus with ketoacidosis 1
C10EN Type 1 diabetes mellitus with ketoacidotic coma 1
C10EP Type 1 diabetes mellitus with exudative maculopathy 1
C10EQ Type 1 diabetes mellitus with gastroparesis 1
C10y0 Diabetes mellitus, juvenile type, with other specified manifestation 1
C10z0 Diabetes mellitus, juvenile type, with unspecified complication 1
L180A Pre-existing type 1 diabetes mellitus in pregnancy 1
C108. Insulin dependent diabetes mellitus 1
C1081 Insulin-dependent diabetes mellitus with ophthalmic complications 1
C1083 Insulin-dependent diabetes mellitus with multiple complications 1
C1084 Unstable insulin dependent diabetes mellitus 1
C1086 Insulin-dependent diabetes mellitus with gangrene 1
C108A Insulin-dependent diabetes without complication 1
C108B Insulin dependent diabetes mellitus with mononeuropathy 1
C108C Insulin dependent diabetes mellitus with polyneuropathy 1
C108D Insulin dependent diabetes mellitus with nephropathy 1
C108E Insulin dependent diabetes mellitus with hypoglycaemic coma 1
C108F Insulin dependent diabetes mellitus with diabetic cataract 1
C108G Insulin dependent diabetes mellitus with peripheral angiopathy 1
C108H Insulin dependent diabetes mellitus with arthropathy 1
Continued
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C108J Insulin dependent diabetes mellitus with neuropathic arthropathy 1
L1805 Pre-existing diabetes mellitus, insulin-dependent 1
X40J4 IDDM - Insulin-dependent diabetes mellitus 1
C1011 Diabetes mellitus, adult onset, with ketoacidosis 2
C1021 Diabetes mellitus, adult onset, with hyperosmolar coma 2
C1031 Diabetes mellitus, adult onset, with ketoacidotic coma 2
C1041 Diabetes mellitus, adult onset, with renal manifestation 2
C1051 Diabetes mellitus, adult onset, with ophthalmic manifestation 2
C1061 Diabetes mellitus, adult onset, with neurological manifestation 2
C1071 Diabetes mellitus, adult onset, with peripheral circulatory disorder 2
C109. Non-insulin dependent diabetes mellitus 2
C1090 Type 2 diabetes mellitus with renal complications 2
C1091 Non-insulin-dependent diabetes mellitus with ophthalmic complications 2
C1092 Type 2 diabetes mellitus with neurological complications 2
C1093 Type 2 diabetes mellitus with multiple complications 2
C1094 Non-insulin-dependent diabetes mellitus with ulcer 2
C1095 Type 2 diabetes mellitus with gangrene 2
C1096 Non-insulin-dependent diabetes mellitus with retinopathy 2
C1097 Type 2 diabetes mellitus - poor control 2
C1099 Non-insulin-dependent diabetes mellitus without complication 2
C109A Non-insulin dependent diabetes mellitus with mononeuropathy 2
C109B Non-insulin dependent diabetes mellitus with polyneuropathy 2
C109C Non-insulin dependent diabetes mellitus with nephropathy 2
C109D Non-insulin dependent diabetes mellitus with hypoglycaemic coma 2
C109E Non-insulin dependent diabetes mellitus with diabetic cataract 2
C109F Non-insulin-dependent diabetes mellitus with peripheral angiopathy 2
C109G Non-insulin dependent diabetes mellitus with arthropathy 2
C109H Non-insulin dependent diabetes mellitus with neuropathic arthropathy 2
C109J Insulin treated Type 2 diabetes mellitus 2
C109K Hyperosmolar non-ketotic state in type 2 diabetes mellitus 2
C10D. Diabetes mellitus autosomal dominant type 2 2
C10F. Type 2 diabetes mellitus 2
C10F0 Type 2 diabetes mellitus with renal complications 2
C10F1 Type 2 diabetes mellitus with ophthalmic complications 2
C10F2 Type 2 diabetes mellitus with neurological complications 2
C10F3 Type 2 diabetes mellitus with multiple complications 2
C10F4 Type 2 diabetes mellitus with ulcer 2
C10F5 Type 2 diabetes mellitus with gangrene 2
C10F6 Type 2 diabetes mellitus with retinopathy 2
C10F7 Type 2 diabetes mellitus - poor control 2
C10F9 Type 2 diabetes mellitus without complication 2
C10FA Type 2 diabetes mellitus with mononeuropathy 2
C10FB Type 2 diabetes mellitus with polyneuropathy 2
C10FC Type 2 diabetes mellitus with nephropathy 2
C10FD Type 2 diabetes mellitus with hypoglycaemic coma 2
C10FE Type 2 diabetes mellitus with diabetic cataract 2
C10FF Type 2 diabetes mellitus with peripheral angiopathy 2
C10FG Type 2 diabetes mellitus with arthropathy 2
C10FH Type 2 diabetes mellitus with neuropathic arthropathy 2
C10FJ Insulin treated Type 2 diabetes mellitus 2
C10FK Hyperosmolar non-ketotic state in type 2 diabetes mellitus 2
C10FL Type 2 diabetes mellitus with persistent proteinuria 2
C10FM Type 2 diabetes mellitus with persistent microalbuminuria 2
C10FN Type 2 diabetes mellitus with ketoacidosis 2
C10FP Type 2 diabetes mellitus with ketoacidotic coma 2
C10FQ Type 2 diabetes mellitus with exudative maculopathy 2
C10FR Type 2 diabetes mellitus with gastroparesis 2
Continued
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C10y1 Diabetes mellitus, adult onset, with other specified manifestation 2
C10z1 Diabetes mellitus, adult onset, with unspecified complication 2
L1806 Pre-existing diabetes mellitus, non-insulin-dependent 2
L180B Pre-existing type 2 diabetes mellitus in pregnancy 2
X40J5 Diabetes mellitus - adult onset 2
X40J6 Insulin treated non-insulin dependent diabetes mellitus 2
C1001 Maturity onset diabetes
L180. Diabetes mellitus during pregnancy, childbirth and the puerperium
L1800 Diabetes mellitus - unspecified whether during pregnancy or the puerperium
L1802 Diabetes mellitus in the puerperium - baby delivered during current episode of care
L1804 Diabetes mellitus in the pueperium - baby delivered during previous episode of care
L1808 GDM - Gestational diabetes mellitus
L1809 Gestational diabetes mellitus
L180z Diabetes mellitus during pregnancy, childbirth or the puerperium NOS
Q44B. Syndrome of infant of mother with gestational diabetes
C10A. Malnutrition-related diabetes mellitus
C10A0 Malnutrition-related diabetes mellitus with coma
C10A1 Malnutrition-related diabetes mellitus with ketoacidosis
C10A2 Malnutrition-related diabetes mellitus with renal complications
C10A3 Malnutrition-related diabetes mellitus with ophthalmic complications
C10A4 Malnutrition-related diabetes mellitus with neurological complications
C10A5 Malnutrition-related diabetes mellitus with peripheral circulatory complications
C10A6 Malnutrition-related diabetes mellitus with multiple complications
C10A7 Malnutrition-related diabetes mellitus without complications
C10AW Malnutrition-related diabetes mellitus with unspecified complications
C10AX Malnutrition-related diabetes mellitus with other specified complications
Cyu21 [X]Malnutrition-related diabetes mellitus with other specified complications
Cyu22 [X]Malnutrition-related diabetes mellitus with unspecified complications
L1807 Pre-existing malnutrition-related diabetes mellitus
X40J8 Malnutrition-related diabetes mellitus - fibrocalculous
X40J9 Malnutrition-related diabetes mellitus - protein-deficient
C10ER Latent autoimmune diabetes mellitus in adult
C10Q. Maturity onset diabetes of the young type 5
XSETH Maturity onset diabetes mellitus in young
XacoB Maturity onset diabetes of the young type 5
66A3. Diabetic on diet only
66A4. Diabetic on oral treatment
66A5. Diabetic on insulin
66AJ1 [Brittle] and/or [labile diabetes]
66o2. Diabetic on non-insulin injectable medication
66o5. Diabetic on oral treatment and glucagon-like peptide 1 receptor agonist
66o6. Diabetic on insulin and glucagon-like peptide 1 receptor agonist
C10.. Diabetes mellitus
C100. Diabetes mellitus with no mention of complication
C100z Diabetes mellitus NOS with no mention of complication
C101. Diabetes mellitus with ketoacidosis
C101y Other specified diabetes mellitus with ketoacidosis
C101z Diabetes mellitus NOS with ketoacidosis
C102. Diabetes mellitus with hyperosmolar coma
C102z Diabetes mellitus NOS with hyperosmolar coma
C103. Diabetes mellitus with ketoacidotic coma
C103y Other specified diabetes mellitus with coma
C103z Diabetes mellitus NOS with ketoacidotic coma
C104. Diabetic nephropathy
C104y Other specified diabetes mellitus with renal complications
C104z Diabetes mellitus with nephropathy NOS
C105. Diabetes mellitus with ophthalmic manifestation
Continued
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C105y Other specified diabetes mellitus with ophthalmic complications
C105z Diabetes mellitus NOS with ophthalmic manifestation
C106. Diabetes mellitus with neuropathy
C106y Other specified diabetes mellitus with neurological complications
C106z Diabetes mellitus NOS with neurological manifestation
C107. Diabetes mellitus with gangrene
C1072 Diabetes mellitus, adult with gangrene
C107y Other specified diabetes mellitus with peripheral circulatory complications
C107z Diabetes mellitus NOS with peripheral circulatory disorder
C108y Other specified diabetes mellitus with multiple complications
C108z Unspecified diabetes mellitus with multiple complications
C10B. Diabetes mellitus induced by steroids
C10B0 Steroid-induced diabetes mellitus without complication
C10C. Diabetes mellitus autosomal dominant
C10FS Maternally inherited diabetes mellitus
C10H. Diabetes mellitus induced by non-steroid drugs
C10H0 Diabetes mellitus induced by non-steroid drugs without complication
C10M. Lipoatrophic diabetes mellitus
C10M0 Lipoatrophic diabetes mellitus without complication
C10y. Diabetes mellitus with other specified manifestation
C10yy Other specified diabetes mellitus with other specified complications
C10yz Diabetes mellitus NOS with other specified manifestation
C10z. Diabetes mellitus with unspecified complication
C10zy Other specified diabetes mellitus with unspecified complications
C10zz Diabetes mellitus NOS with unspecified complication
C11y0 Steroid-induced diabetes
Cyu2. [X]Diabetes mellitus
Cyu20 [X]Other specified diabetes mellitus
Cyu23 [X]Unspecified diabetes mellitus with renal complications
L1801 Diabetes mellitus during pregnancy - baby delivered
L1803 Diabetes mellitus during pregnancy - baby not yet delivered
L180X Pre-existing diabetes mellitus, unspecified
Lyu29 [X]Pre-existing diabetes mellitus, unspecified
Q440. Maternal diabetes syndrome
Q441. Neonatal diabetes mellitus
X40J7 Jamaica type diabetes
XE10G Diabetes mellitus with renal manifestation
XE10H Diabetes mellitus with neurological manifestation
XE10I Diabetes mellitus with peripheral circulatory disorder
XE12M Diabetes with other complications
ICD10_CODE Description Modifier TYPE_NUM
E10 Type 1 diabetes mellitus 1
E100 Type 1 diabetes mellitus with coma 1
E101 Type 1 diabetes mellitus with ketoacidosis 1
E102 Type 1 diabetes mellitus with renal complications 1
E103 Type 1 diabetes mellitus with ophthalmic complications 1
E104 Type 1 diabetes mellitus with neurological complications 1
E105 Type 1 diabetes mellitus with peripheral circulatory complcaitions 1
E106 Type 1 diabetes mellitus with other spicified complications 1
E107 Type 1 diabetes mellitus with multiple complications 1
E108 Type 1 diabetes mellitus with unspecified complications 1
E109 Type 1 diabetes mellitus without complications 1
E11 Type 2 diabetes mellitus 2
E110 Type 2 diabetes mellitus with coma 2
E111 Type 2 diabetes mellitus with ketoacidosis 2
E112 Type 2 diabetes mellitus with renal complications 2
Continued
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E113 Type 2 diabetes mellitus with ophthalmic complications 2
E114 Type 2 diabetes mellitus with neurological complications 2
E115 Type 2 diabetes mellitus with peripheral circulatory complcaitions 2
E116 Type 2 diabetes mellitus with other spicified complications 2
E117 Type 2 diabetes mellitus with multiple complications 2
E118 Type 2 diabetes mellitus with unspecified complications 2
E119 Type 2 diabetes mellitus without complications 2
E12 Malnutrition related diabetes mellitus
E120 Malnutrition related diabetes mellitus with coma
E121 Malnutrition related diabetes mellitus with ketoacidosis
E122 Malnutrition related diabetes mellitus with renal complications
E123 Malnutrition related diabetes mellitus with ophthalmic complications
E124 Malnutrition related diabetes mellitus with neurological complications
E125 Malnutrition related diabetes mellitus with peripheral circulatory complcaitions
E126 Malnutrition related diabetes mellitus with other spicified complications
E127 Malnutrition related diabetes mellitus with multiple complications
E128 Malnutrition related diabetes mellitus with unspecified complications
E129 Malnutrition related diabetes mellitus without complications
E13 Other specified diabetes mellitus
E130 Other specified diabetes mellitus with coma
E131 Other specified diabetes mellitus with ketoacidosis
E132 Other specified diabetes mellitus with renal complications
E133 Other specified diabetes mellitus with ophthalmic complications
E134 Other specified diabetes mellitus with neurological complications
E135 Other specified diabetes mellitus with peripheral circulatory complcaitions
E136 Other specified diabetes mellitus with other spicified complications
E137 Other specified diabetes mellitus with multiple complications
E138 Other specified diabetes mellitus with unspecified complications
E139 Other specified diabetes mellitus without complications
E14 Unspecified diabetes mellitus
E140 Unspecified diabetes mellitus with coma
E141 Unspecified diabetes mellitus with ketoacidosis
E142 Unspecified diabetes mellitus with renal complications
E143 Unspecified diabetes mellitus with ophthalmic complications
E144 Unspecified diabetes mellitus with neurological complications
E145 Unspecified diabetes mellitus with peripheral circulatory complcaitions
E146 Unspecified diabetes mellitus with other spicified complications
E147 Unspecified diabetes mellitus with multiple complications
E148 Unspecified diabetes mellitus with unspecified complications
E149 Unspecified diabetes mellitus without complications
O24 Diabetes mellitus in pregnancy
O240 Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, type 1 1
O241 Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, type 2 2
O242 Diabetes mellitus in pregnancy: Pre-existing malnutrition-related diabetes mellitus
O243 Diabetes mellitus in pregnancy: Pre-existing diabetes mellitus, unspecified
O244 Diabetes mellitus arising in pregnancy
O249 Diabetes mellitus in pregnancy, unspecified
P700 Syndrome of infant of mother with gestational diabetes
P702 Neonatal diabetes mellitus
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f111. INSULIN 100 iu/mL injection 10mL
f112. ∗HYPURIN injection 10mL
f12.. Soluble neutral insulin
f121. NEUTRAL INSULIN 100 iu/mL injection 10mL
f122. HYPURIN NEUTRAL 100 iu/mL injection 10mL
f123. Neusulin 100 iu/mL injection vial
f124. Quicksol 100 iu/mL injection vial
f125. Velosulin 100 iu/mL injection 10mL
f126. VELOSULIN CARTRIDGE 100 iu/mL injection 5.7mL
f127. HUMAN ACTRAPID 100 iu/mL injection 10mL
f128. HUMAN ACTRAPID 100 iu/mL penfill cartridges
f129. Human Velosulin 100 iu/mL injection 10mL
f12A. HUMAN ACTRAPID 100 iu/mL penfill cartridges 1.5mL
f12B. HUMAN ACTRAPID 100 iu/mL preloaded injection pen 3mL
f12C. Humaject S 100 iu/mL prefilled pen
f12D. Pork Actrapid 100 iu/mL injection 10mL
f12E. Neutral insulin 100 iu/mL injection cartridge
f12F. HYPURIN BOVINE NEUTRAL 100 iu/mL injection cartridge 1.5mL
f12G. HYPURIN PORCINE NEUTRAL 100 iu/mL injection cartridge 1.5mL
f12H. Hypurin Bovine Neutral 100 iu/mL injection 10mL
f12I. Hypurin Porcine Neutral 100 iu/mL injection 10mL
f12J. Actrapid (human) Penfill 100 iu/mL cartridge 3mL
f12K. PORK ACTRAPID 100 iu/mL injection 10mL
f12L. INSUMAN RAPID 100 iu/mL injection vials 5mL
f12M. Insuman Rapid 100 iu/mL injection cartridge 3mL
f12N. BD ULTRA PEN 3.0mL 1 unit device
f12P. BD ULTRA PEN 1.5mL 1 unit device
f12Q. Insuman Rapid OptiSet 100 iu/mL prefilled pen 3mL
f12R. Human Velosulin (pyr) 100 iu/mL injection 10mL
f12S. Hypurin Bovine Neutral 100 iu/mL injection cartridge 3mL
f12T. Hypurin Porcine Neutral 100 iu/mL injection cartridge 3mL
f12U. EXUBERA 1mg powder for inhalation
f12V. EXUBERA 3mg powder for inhalation
f12W. HUMAN INSULIN 1mg powder for inhalation
f12X. HUMAN INSULIN 3mg powder for inhalation
f12Y. INSUMAN INFUSAT 100 iu/mL soln for inj cartridges 3.15mL
f12Z. INSUMAN INFUSAT 100 iu/mL solution for injection vials 10mL
f12a. Humulin S 100 iu/mL injection 10mL
f12b. ∗NOVOPEN
f12c. ∗PENJECT
f12d. PUR-IN NEUTRAL 100 iu/mL vials 10mL
f12e. PUR-IN NEUTRAL 100 iu/mL cartridges 3mL
f12f. ∗AUTOPEN
f12g. HUMULIN S 100 iu/mL cartridges 1.5mL
f12h. NovoPen II device
f12i. ∗BD PEN device
f12j. ∗PUR-IN PEN device
f12k. ∗PUR-IN PEN 1 device
f12m. ∗PUR-IN PEN 2 device
f12n. ∗PUR-IN PEN 4 device
f12p. Diapen 1 device
f12q. Diapen 2 device
f12r. NovoPen I device
f12s. Humulin S 100 iu/mL cartridges 3mL
f12t. ∗AUTOPEN 1.5mL one unit device
Continued
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f12u. ∗AUTOPEN 1.5mL two unit device
f12v. ∗AUTOPEN 3mL two unit device
f12y. HUMAN INSULIN 100 units/mL injection cartridge
f12z. Human insulin 100 iu/mL injection vial
f13.. Insulin lispro
f131. INSULIN LISPRO 100 iu/mL vials
f132. HUMALOG 100 iu/mL injection 10mL
f133. INSULIN LISPRO 100 iu/mL cartridges
f134. Humalog 100 iu/mL cartridges 1.5mL
f135. Humalog 100 iu/mL cartridge 3mL
f136. Insulin lispro 100 iu/mL prefilled pen
f137. Humalog-Pen 100 iu/mL prefilled pen 3mL
f138. HUMALOG KWIKPEN 100 iu/mL prefilled pen 3mL
f139. HUMALOG KWIKPEN 200 iu/mL prefilled pen 3mL
f13A. INSULIN LISPRO 200 iu/mL prefilled pen
f14.. Insulin aspart
f141. NOVORAPID 100 units/mL injection vial
f142. NovoRapid NovoLet 100 units/mL prefilled syringe 3mL
f143. NovoRapid Penfill 100 units/mL cartridge 3mL
f144. NOVORAPID FLEXPEN 100 units/mL prefilled pen 3mL
f145. NOVORAPID FLEXTOUCH 100 units/mL soln for injection pen 3mL
f146. NOVORAPID PUMPCART 100 units/mL soln for inj cartridges 1.6mL
f14w. INSULIN ASPART 100 units/mL prefilled pen
f14x. Insulin aspart 100 units/mL injection vial
f14y. INSULIN ASPART 100 units/mL prefilled syringe
f14z. INSULIN ASPART 100 units/mL cartridges
f15.. INSULIN GLULISINE
f151. Apidra 100 iu/mL injection vials 10mL
f152. APIDRA 100 iu/mL injection cartridges 3mL
f153. Apidra 100 iu/mL OptiSet prefilled pen 3mL
f154. APIDRA 100 iu/mL OptiClik cartridges 3mL
f155. APIDRA 100 iu/mL SoloStar prefilled pen 3mL
f15x. Insulin glulisine 100 iu/mL injection prefilled pen
f15y. INSULIN GLULISINE 100 iu/mL injection cartridges
f15z. INSULIN GLULISINE 100 iu/mL injection vials
f2... MEDIUM/LONG-ACTING INSULINS
f21.. BIPHASIC INSULIN
f211. Rapitard MC 100 iu/mL injection 10mL
f212. ∗PENMIX cartridges 1.5mL
f21z. Biphasic insulin 100 units/mL injection vial
f22.. IZS - insulin zinc suspension
f221. Insulin zinc lente 100 iu/mL injection 10mL
f222. HYPURIN LENTE 100 iu/mL injection 10mL
f223. LENTARD MC 100 iu/mL injection 10mL
f224. ∗NEULENTE 100 iu/mL injection
f225. Tempulin 100 iu/mL injection
f226. Human Monotard 100 iu/mL injection 10mL
f227. Humulin Lente 100 iu/mL injection 10mL
f228. HYPURIN BOVINE LENTE 100 iu/mL injection 10mL
f22y. Human insulin zinc suspension 100 units/mL injection vial
f22z. Insulin zinc suspension 100 units/mL injection vial
f23.. INSULIN ZINC SUSPENSION - AMORPHOUS
f231. SEMITARD MC 100 iu/mL injection 10mL
f23z. Insulin zinc amorphous suspension 100 units/mL injection vial
f24.. Insulin zinc suspension (crystalline)
f241. Human Ultratard 100 iu/mL injection 10mL
f242. HUMULIN ZN 100 iu/mL injection 10mL
Continued
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f24z. Insulin zinc crystalline human suspension 100 units/mL injection vial
f25.. Isophane insulin
f251. ISOPHANE INSULIN 100 iu/mL injection 10mL
f252. HYPURIN ISOPHANE 100 iu/mL injection 10mL
f253. Insulatard 100 iu/mL injection 10mL
f254. ∗MONOPHANE 100 iu/mL injection
f255. Neuphane 100 iu/mL injection
f256. ∗INITARD 50/50 injection 10mL
f257. ∗MIXTARD injection 10mL
f258. Human Insulatard 100 iu/mL injection 10mL
f259. HUMAN PROTAPHANE 100 iu/mL injection 10mL
f25A. HUMULIN I 100 iu/mL prefilled pen 3mL
f25B. Insuman Basal Optiset 100 iu/mL prefilled pen 3mL
f25C. Insulatard InnoLet 100units/mL prefilled syringe 3mL
f25D. INSULATARD FLEXPEN 100 iu/mL prefilled pen 3mL
f25E. HYPURIN BOVINE ISOPHANE 100 iu/mL injection cartridge 3mL
f25F. Hypurin Porcine Isophane 100 iu/mL injection cartridge 3mL
f25G. HUMULIN I KWIKPEN 100 iu/mL prefilled pen 3mL
f25H. INSUMAN BASAL SOLOSTAR 100 iu/mL prefilled pen 3mL
f25W. Human isophane insulin 100 units/mL prefilled syringe
f25X. HUMAN ISOPHANE INSULIN 100 units/mL injection cartridge
f25Y. HUMAN ISOPHANE INSULIN 100 units/mL injection vials
f25Z. Isophane insulin 100 iu/mL injection vial
f25a. Humulin I 100 iu/mL injection 10mL
f25b. HUMAN ACTRAPHANE injection 10mL
f25c. ∗HUMAN INITARD injection 10mL
f25d. Human Mixtard injection 10mL
f25e. ∗HUMULIN M1 injection 10mL
f25f. Humulin M2 injection 10mL
f25g. Humulin M3 injection 10mL
f25h. ∗HUMULIN M4 injection 10mL
f25i. HUMAN PROTAPHANE penfill 1.5mL
f25j. Pur-In Isophane 100 iu/mL vials 10mL
f25k. PUR-IN ISOPHANE 100 iu/mL cartridges 3mL
f25l. HUMULIN I 100 iu/mL cartridges 1.5mL
f25m. Human Insulatard 100 iu/mL preloaded injection pen 3mL
f25n. HUMAJECT I 100 iu/mL prefilled pen
f25o. HUMULIN I 100 iu/mL cartridges 3mL
f25p. Human Insulatard ge 100 iu/mL injection 10mL
f25q. Human Insulatard Penfill 1.5mL
f25r. PORK INSULATARD 100 units/mL injection 10mL
f25s. ISOPHANE INSULIN 100 iu/mL injection cartridge
f25t. Hypurin Bovine Isophane 100 iu/mL injection cartridge 1.5mL
f25u. Hypurin Porcine Isophane 100 iu/mL injection cartridge 1.5mL
f25v. Hypurin Bovine Isophane 100 iu/mL injection 10mL
f25w. Hypurin Porcine Isophane 100 iu/mL injection 10mL
f25x. Insulatard Penfill cartridge 3mL
f25y. Insuman Basal 100 iu/mL injection vial 5mL
f25z. INSUMAN BASAL 100 iu/mL injection cartridge 3mL
f26.. PROTAMINE ZINC INSULIN
f261. HYPURIN PROTAMINE ZINC injection 10mL
f262. HYPURIN BOVINE PROTAMINE ZINC 100 iu/mL injection 10mL
f26z. Protamine zinc insulin 100 units/mL injection vial
f27.. BIPHASIC ISOPHANE INSULIN
f271. Mixtard 30/70 injection 10mL
f272. ∗PENMIX 30/70 cartridges 1.5mL
f273. Pur-In Mix 15/85 vials 10mL
Continued
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f274. Pur-In Mix 15/85 cartridges 3mL
f275. Pur-In Mix 25/75 vials 10mL
f276. PUR-IN MIX 25/75 cartridges 3mL
f277. ∗PUR-IN MIX 50/50 vials 10mL
f278. Pur-In Mix 50/50 cartridges 3mL
f279. ∗HUMULIN M1 10/90 vials 10mL
f27A. HUMAJECT M1 100 iu/mL prefilled pen
f27B. Humaject M2 100 iu/mL prefilled pen
f27C. HUMAJECT M3 100 iu/mL prefilled pen
f27D. HUMAJECT M4 100 iu/mL prefilled pen
f27E. Humaject M5 100 iu/mL prefilled pen
f27F. HUMULIN M4 40/60 cartridges 3mL
f27G. HUMULIN M5 50/50 cartridges 3mL
f27H. HUMAN MIXTARD 30 ge injection 10mL
f27I. Hypurin Porcine Biphasic Isophane 30/70 injection cartridge 3mL
f27J. PenMix 10/90 cartridges 1.5mL
f27K. Human Mixtard 20 Penfill 1.5mL
f27L. HUMAN MIXTARD 30 PENFILL cartridges 1.5mL
f27M. HUMAN MIXTARD 40 PENFILL cartridges 1.5mL
f27N. Human Mixtard 50 Penfill 1.5mL
f27O. Mixtard 30 InnoLet 100 units/mL prefilled syringe 3mL
f27P. PenMix 10/90 (pyr) 100 iu/mL preloaded injection pen
f27Q. HUMAN MIXTARD 20 prefilled pen
f27R. HUMAN MIXTARD 30 prefilled pen
f27S. HUMAN MIXTARD 40 prefilled pen
f27T. PenMix 50/50 (pyr) 100 iu/mL preloaded injection pen
f27V. Pork Mixtard 30 injection 10mL
f27W. Human Mixtard 50 vial 10mL
f27X. Hypurin Porcine Biphasic Isophane 30/70 injection 10mL
f27Y. HYPURIN PORCINE BIPHASIC ISOPHANE 30/70 injection cartridge 1.5mL
f27Z. Insuman Comb 25 100 iu/mL injection vial 5mL
f27a. HUMULIN M1 10/90 cartridges 1.5mL
f27b. Humulin M2 20/80 vials 10mL
f27c. Humulin M2 20/80 cartridges 1.5mL
f27d. Humulin M3 30/70 vials 10mL
f27e. Humulin M3 30/70 cartridges 1.5mL
f27f. Humulin M4 40/60 vials 10mL
f27g. Humulin M4 40/60 cartridges 1.5mL
f27h. ∗INITARD 50/50 injection 10mL
f27i. HUMAN ACTRAPHANE 30/70 injection 10mL
f27j. Human Mixtard 30/70 injection 10mL
f27k. HUMAN INITARD 50/50 injection 10mL
f27l. ∗PENMIX 10/90 cartridges 1.5mL
f27m. ∗PENMIX 20/80 cartridges 1.5mL
f27n. ∗PENMIX 40/60 cartridges 1.5mL
f27o. ∗PENMIX 50/50 cartridges 1.5mL
f27p. PENMIX 30/70 preloaded injection pen
f27q. PENMIX 10/90 preloaded injection pen
f27r. PENMIX 20/80 preloaded injection pen
f27s. PENMIX 40/60 preloaded injection pen
f27t. PENMIX 50/50 preloaded injection pen
f27u. Humulin M5 50/50 injection vial 10mL
f27v. HUMULIN M5 50/50 cartridges 1.5mL
f27w. Humulin M1 10/90 cartridges 3mL
f27x. Humulin M2 20/80 cartridges 3mL
f27y. Insuman Comb 25 100 iu/mL injection cartridge 3mL
f27z. HUMULIN M3 30/70 cartridges 3mL
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f28.. Biphasic isophane insulin 2
f281. Mixtard 10 (human) Penfill cartridge 3mL
f282. Mixtard 20 (human) Penfill cartridge 3mL
f283. Mixtard 30 (human) Penfill cartridge 3mL
f284. Mixtard 40 (human) Penfill cartridge 3mL
f285. Mixtard 50 Penfill cartridge 3mL
f286. INSUMAN COMB 15 100 iu/mL injection cartridge 3mL
f287. INSUMAN COMB 50 100 iu/mL injection vials 5mL
f288. INSUMAN COMB 15 OPTISET 100 iu/mL prefilled pen 3mL
f289. INSUMAN COMB 25 OPTISET 100 iu/mL prefilled pen 3mL
f28A. Insuman Comb 50 OptiSet 100 iu/mL prefilled pen 3mL
f28B. Insuman Comb 15 100 iu/mL injection vial 5mL
f28C. Insuman Comb 50 100 iu/mL injection cartridge 3mL
f28D. HUMULIN M3 100 iu/mL prefilled pen 3mL
f28E. HUMULIN M3 KWIKPEN 100 iu/mL prefilled pen 3mL
f28F. INSUMAN COMB 25 SOLOSTAR 100 iu/mL prefilled pen 3mL
f29.. INSULIN GLARGINE
f291. Insulin glargine 100 iu/mL injection cartridge
f292. INSULIN GLARGINE 100 iu/mL injection vials
f293. Insulin glargine 100 iu/mL prefilled pen
f294. Lantus 100 iu/mL injection cartridge 3mL
f295. Lantus 100 iu/mL injection vial 10mL
f296. LANTUS 100 iu/mL OptiSet prefilled pen 3mL
f297. Lantus 100 iu/mL OptiClik cartridges 3mL
f298. LANTUS 100 iu/mL SoloStar prefilled pen 3mL
f299. TOUJEO 300 iu/mL SoloStar prefilled pen 1.5mL
f29A. INSULIN GLARGINE 300 iu/mL prefilled pen
f29B. ABASAGLAR 100 iu/mL solution for injection cartridges 3mL
f29C. ABASAGLAR KWIKPEN 100 iu/mL soln for inj prefilled pen 3mL
f2A.. INSULIN DETEMIR
f2A1. Levemir Penfill 100 iu/mL injection cartridge 3mL
f2A2. Levemir FlexPen 100 iu/mL prefilled pen 3mL
f2A3. LEVEMIR INNOLET 100 iu/mL prefilled syringe 3mL
f2Ax. INSULIN DETEMIR 100 iu/mL prefilled syringe
f2Ay. INSULIN DETEMIR 100 iu/mL prefilled pen
f2Az. INSULIN DETEMIR 100 iu/mL injection cartridges
f2B.. INSULIN DEGLUDEC
f2B1. TRESIBA FLEXTOUCH 100 iu/mL prefilled pen 3mL
f2B2. INSULIN DEGLUDEC 100 iu/mL prefilled pen
f2B3. TRESIBA FLEXTOUCH 200 iu/mL prefilled pen 3mL
f2B4. INSULIN DEGLUDEC 200 iu/mL prefilled pen
f2B5. TRESIBA PENFILL 100 iu/mL injection cartridges
f2B6. INSULIN DEGLUDEC 100 iu/mL injection cartridges
f2C.. INSULIN DEGLUDEC+ LIRAGLUTIDE
f2C1. XULTOPHY 100 iu/mL/3.6mg/mL soln for inj prefilled pen 3mL
f2C2. INSULIN DEGLUDEC+LIRAGLUTIDE 100 iu/mL/3.6mg/mL soln inj pen
fw... Short with intermediate-acting insulins
fw1.. Biphasic isophane insulin lispro
fw11. Humalog Mix25 100 iu/mL cartridge 3mL
fw12. Humalog Mix25 100 iu/mL prefilled pen 3mL
fw13. HUMALOG MIX50 100 iu/mL prefilled pen 3mL
fw14. HUMALOG MIX50 100 iu/mL cartridges 3mL
fw15. HUMALOG MIX25 KWIKPEN 100 iu/mL prefilled pen 3mL
fw16. HUMALOG MIX50 KWIKPEN 100 iu/mL prefilled pen 3mL
fw2.. BIPHASIC INSULIN ASPART
fw21. NovoMix 30 Penfill 100 units/mL injection cartridge 3mL
fw22. NovoMix 30 FlexPen 100 units/mL injection prefilled pen 3mL
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x005R Actrapid (pyr) 100 iu/mL injection vial
x005T Human Insulatard (emp) 100 iu/mL injection vial
x005X Human Insulatard ge 100 units/mL injection vial
x005Y Human Insulatard 100 units/mL Penfill
x006L Hypurin Isophane (bovine) 100 iu/mL injection vial
x006M Hypurin Lente (bovine) 100 iu/mL injection vial
x006N Hypurin Bovine Neutral 100 iu/mL injection vial
x006O Hypurin Protamine Zinc (bovine) 100 units/mL injection vial
x006e Insulatard (porcine) 100 iu/mL injection vial
x006f Insulin product
x008B Neutral insulin 100 iu/mL injection vial
x00Bt Pork Actrapid 100 iu/mL injection vial
x01LZ Actrapid NovoLet 100 iu/mL prefilled pen







x01Lh Insulatard NovoLet 100 units/mL prefilled pen
x01UL Glass U100 insulin syringe
x01UM Disposable U100 insulin syringe
x02KN Human insulin 100 units/mL prefilled pen
x02KO Human isophane insulin 100 units/mL prefilled pen




x03eI Humalog 100 iu/mL injection vial
x03eJ Humalog 100 iu/mL injection cartridge
x03eK Humalog
x03ln Hypurin Bovine Neutral 100 iu/mL injection cartridge
x03lo Hypurin Bovine Isophane 100 iu/mL injection cartridge
x03lp Hypurin Porcine Neutral 100 iu/mL injection cartridge
x03lq Hypurin Porcine Isophane 100 iu/mL injection cartridge
x03lv Hypurin Porcine Neutral 100 iu/mL injection vial
x03lw Hypurin Porcine Isophane 100 iu/mL injection vial
x03lx Hypurin biphasic isophane insulin
x03ly Hypurin Porcine 30/70 Mix injection vial
x03lz Hypurin Porcine 30/70 Mix injection cartridge
x049L Human Actrapid Penfill
x049M Human Insulatard ge
x049q Hypurin Bovine Isophane
x049r Hypurin Bovine Lente
x049s Hypurin Bovine Neutral
x049t Hypurin Bovine Protamine Zinc
x049u Hypurin Porcine Biphasic Isophane
x04wm Humalog biphasic isophane insulin lispro
x04wn Humalog Mix25 100 iu/mL cartridge
x04wo Humalog Mix25 100 iu/mL prefilled pen
x04wp Humalog Mix25
x051f Hypurin Porcine
x053d NovoRapid NovoLet 100 units/mL prefilled syringe
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x053h NovoRapid Penfill
x056T Insuman Rapid 100 iu/mL injection vial
x056U Insuman Rapid 100 iu/mL injection cartridge
x056X Insuman Basal 100 iu/mL injection vial
x056Y Insuman Basal
x056Z Insuman Basal 100 iu/mL injection cartridge
x056a Insuman Comb insulin
x056b Insuman Comb 25 100 iu/mL injection vial
x056c Insuman Comb 25 100 iu/mL injection cartridge
x056d Insuman Rapid
x056e Insuman Comb 25
x059L Humalog-Pen 100 iu/mL prefilled pen
x059M Humalog-Pen
x059N Humalog Mix50 100 iu/mL prefilled pen
x059P Humalog Mix50
x05Cm Insuman Comb 15 100 iu/mL injection cartridge
x05Cn Insuman Comb 50 100 iu/mL injection vial
x05Co Insuman Comb 15
x05Cp Insuman Comb 50
x05EY Insuman Basal OptiSet 100 iu/mL prefilled pen
x05EZ Insuman Basal OptiSet
x05Ea Insuman Rapid OptiSet 100 iu/mL prefilled pen
x05Eb Insuman Rapid OptiSet
x05Ec Insuman Comb 15 OptiSet 100 iu/mL prefilled pen
x05Ed Insuman Comb 25 OptiSet 100 iu/mL prefilled pen
x05Ee Insuman Comb 50 OptiSet 100 iu/mL prefilled pen
x05Ef Insuman Comb 15 OptiSet
x05Eg Insuman Comb 25 OptiSet
x05Eh Insuman Comb 50 OptiSet
x05FF Insuman Comb 15 100 iu/mL injection vial
x05FG Insuman Comb 50 100 iu/mL injection cartridge
x05MR Biphasic insulin - chemical
x05MS Biphasic isophane insulin - chemical
x05Xe Insulatard InnoLet 100 units/mL prefilled syringe
x05Xf Insulatard InnoLet
x05d0 NovoMix
x05d1 Insulin biphasic aspart 30/70 100 units/mL injection cartridge 3mL
x05d2 Insulin biphasic aspart 30/70 100 units/mL injection prefilled pen 3mL
x05fE Lantus
x05fF Lantus 100 iu/mL injection cartridge
x05fG Lantus 100 iu/mL injection vial
x05fH Lantus 100 iu/mL OptiSet prefilled pen
x05fv Disposable insulin U100 0.3mL syringe+needle
x05fw Disposable insulin U100 0.5mL syringe+needle
x05fx Disposable insulin U100 1mL syringe+needle
x05gU NovoRapid FlexPen
x05gV Insulatard FlexPen
x05gW Insulatard FlexPen 100 iu/mL prefilled pen
x05gX NovoRapid FlexPen 100 units/mL prefilled pen
x05tf Levemir Penfill 100 iu/mL injection cartridge
x05tg Levemir
x05th Levemir FlexPen 100 iu/mL prefilled pen
x05ya Apidra 100 iu/mL injection vial
x05yb Apidra 100 iu/mL injection cartridge
x05yc Apidra
x05zZ Lantus 100 iu/mL OptiClik cartridge
x05zr Apidra 100 iu/mL OptiSet prefilled pen
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f311. Dimelor 500mg tablet
f31z. Acetohexamide 500mg tablet
f32.. CHLORPROPAMIDE
f321. Chlorpropamide 100mg tablet
f322. Chlorpropamide 250mg tablet
f323. Diabinese 100mg tablet
f324. ∗DIABINESE 250mg tablets
f325. Glymese 250mg tablet
f33.. Glybenclamide
f331. GLIBENCLAMIDE 2.5mg tablets
f332. GLIBENCLAMIDE 5mg tablets
f333. Daonil 5mg tablet
f334. ∗SEMI-DAONIL 2.5mg tablets
f335. ∗EUGLUCON 2.5mg tablets
f336. ∗EUGLUCON 5mg tablets
f337. ∗LIBANIL 2.5mg tablets
f338. Libanil 5mg tablet
f339. Malix 2.5mg tablet
f33a. ∗MALIX 5mg tablets
f33b. ∗DAONIL CP 5mg tablets
f33c. Semi-daonil CP 2.5mg tablets
f33d. ∗DIABETAMIDE 2.5mg tablets
f33e. ∗DIABETAMIDE 5mg tablets
f33f. ∗CALABREN 2.5mg tablets
f33g. Calabren 5mg tablet
f34.. Glibornuride
f341. ∗GLUTRIL 25mg tablets
f34z. ∗GLIBORNURIDE 25mg tablets
f35.. GLICLAZIDE
f351. DIAMICRON 80mg tablets
f352. DIAGLYK 80mg tablets
f353. Vivazide 80mg tablet
f354. DIAMICRON MR 30mgm/r tablets
f355. NAZDOL MR 30mgm/r tablets
f356. EDICIL MR 30mgm/r tablets
f357. ZICRON 40mg tablets
f358. VITILE XL 30mgm/r tablets
f359. LAAGLYDA MR 60mgm/r tablets
f35A. VAMJU 30mgm/r tablets
f35B. VAMJU 60mgm/r tablets
f35C. BILXONA 30mgm/r tablets
f35D. BILXONA 60mgm/r tablets
f35w. GLICLAZIDE 60mgm/r tablets
f35x. GLICLAZIDE 40mg tablets
f35y. GLICLAZIDE 30mgm/r tablets
f35z. GLICLAZIDE 80mg tablets
f36.. Glipizide product
f361. GLIPIZIDE 5mg tablets
f362. ∗GLIBENESE 5mg tablets
f363. ∗MINODIAB 2.5mg tablets
f364. Minodiab 5mg tablet
f36y. ∗GLIPIZIDE 5mg tablets
f36z. Glipizide 2.5mg tablet
f37.. Gliquidone
f371. ∗GLURENORM 30mg tablets
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f37z. ∗GLIQUIDONE 30mg tablets
f38.. Glymidine
f381. Gondafon 500mg tablet
f38z. ∗GLYMIDINE 500mg tablets
f39.. TOLAZAMIDE
f391. TOLANASE 100mg tablets
f392. TOLANASE 250mg tablets
f39y. Tolazamide 100mg tablet
f39z. Tolazamide 250mg tablet
f3A.. GLIMEPIRIDE
f3A1. Glimepiride 2mg tablet
f3A2. AMARYL 2mg tablets
f3A3. GLIMEPIRIDE 1mg tablets
f3A4. Glimepiride 3mg tablet
f3A5. Glimepiride 4mg tablet
f3A6. Amaryl 1mg tablet
f3A7. Amaryl 3mg tablet
f3A8. AMARYL 4mg tablets
f3A9. NIDDARYL 1mg tablets
f3AA. NIDDARYL 2mg tablets
f3AB. NIDDARYL 3mg tablets
f3AC. NIDDARYL 4mg tablets
f3a.. TOLBUTAMIDE
f3a1. TOLBUTAMIDE 500mg tablets
f3a2. GLYCONON 500mg tablets
f3a3. ∗PRAMIDEX 500mg tablets
f3a4. Rastinon 500mg tablet
f4... Biguanide
f41.. Metformin hydrochloride
f411. Glucophage 500mg tablet
f412. Glucophage 850mg tablet
f413. ∗ORABET 500mg tablets
f414. ∗ORABET 850mg tablets
f415. Glucamet 500 tablet
f416. Glucamet 850 tablet
f417. Glucophage SR 500mgm/r tablet
f418. METSOL 500mg/5mL oral solution
f419. GLUCOPHAGE SR 750mgm/r tablets
f41A. GLUCOPHAGE SR 1000mgm/r tablets
f41B. BOLAMYN SR 500mgm/r tablets
f41C. GLUCOPHAGE 500mg/sachet oral powder
f41D. GLUCOPHAGE 1000mg/sachet oral powder
f41E. METABET SR 500mgm/r tablets
f41F. METABET SR 1000mgm/r tablets
f41G. GLUCIENT SR 500mgm/r tablets
f41H. DIAGEMET XL 500mgm/r tablets
f41I. SUKKARTO SR 500mgm/r tablets
f41J. SUKKARTO SR 1000mgm/r tablets
f41s. METFORMIN HYDROCHLORIDE 1000mg/sachet oral powder
f41t. METFORMIN HYDROCHLORIDE 500mg/sachet oral powder
f41u. METFORMIN HYDROCHLORIDE 1000mgm/r tablets
f41v. METFORMIN HYDROCHLORIDE 750mgm/r tablets
f41w. METFORMIN HYDROCHLORIDE 500mg/5mL oral solution
f41x. Metformin hydrochloride 500mgm/r tablet
f41y. METFORMIN HYDROCHLORIDE 500mg tablets
f41z. METFORMIN HYDROCHLORIDE 850mg tablets
ft... Other drugs used in diabetes
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ft1.. ACARBOSE
ft11. Acarbose 50mg tablet
ft12. ACARBOSE 100mg tablets
ft13. Glucobay 50mg tablet
ft14. GLUCOBAY 100 tablets
ft2.. Troglitazone
ft21. Troglitazone 200mg tablet
ft22. ∗TROGLITAZONE 300mg tablets
ft23. Troglitazone 400mg tablet
ft24. ∗ROMOZIN 200mg tablets
ft25. ∗ROMOZIN 300mg tablets
ft26. Romozin 400mg tablet
ft3.. REPAGLINIDE
ft31. Repaglinide 0.5mg tablet
ft32. Repaglinide 1mg tablet
ft33. Repaglinide 2mg tablet
ft34. ∗NOVONORM 0.5mg tablets
ft35. ∗NOVONORM 1mg tablets
ft36. NovoNorm 2mg tablet
ft37. PRANDIN 500micrograms tablets
ft38. PRANDIN 1mg tablets
ft39. PRANDIN 2mg tablets
ft4.. Rosiglitazone
ft41. ∗AVANDIA 4mg tablets
ft42. ∗AVANDIA 8mg tablets
ft43. Avandamet 1mg / 500mg tablet
ft44. Avandamet 2mg / 500mg tablet
ft45. AVANDAMET 2mg / 1000mg tablets
ft46. Avandamet 4mg / 1000mg tablet
ft4u. Rosiglitazone 2mg / Metformin 1000mg tablet
ft4v. ROSIGLITAZONE 4mg / METFORMIN 1000mg tablets
ft4w. Rosiglitazone 2mg / metformin 500mg tablet
ft4x. ROSIGLITAZONE 1mg / METFORMIN 500mg tablets
ft4y. Rosiglitazone 8mg tablet
ft4z. ∗ROSIGLITAZONE 4mg tablets
ft5.. PIOGLITAZONE
ft51. ACTOS 15mg tablets
ft52. Actos 30mg tablet
ft53. ACTOS 45mg tablets
ft54. GLIDIPION 15mg tablets
ft55. GLIDIPION 30mg tablets
ft56. GLIDIPION 45mg tablets
ft5x. PIOGLITAZONE 45mg tablets
ft5y. PIOGLITAZONE 30mg tablets
ft5z. PIOGLITAZONE 15mg tablets
ft6.. Nateglinide
ft61. STARLIX 60mg tablets
ft62. Starlix 120mg tablet
ft63. STARLIX 180mg tablets
ft6x. NATEGLINIDE 180mg tablets
ft6y. NATEGLINIDE 120mg tablets
ft6z. Nateglinide 60mg tablet
ft7.. METFORMIN+PIOGLITAZONE
ft71. COMPETACT 15mg/850mg tablets
ft7z. METFORMIN 850mg/PIOGLITAZONE 15mg tablets
ft8.. SITAGLIPTIN
ft81. JANUVIA 100mg tablets
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ft82. JANUVIA 50mg tablets
ft83. JANUVIA 25mg tablets
ft8x. SITAGLIPTIN 25mg tablets
ft8y. SITAGLIPTIN 50mg tablets
ft8z. SITAGLIPTIN 100mg tablets
ft9.. EXENATIDE
ft91. BYETTA 5micrograms/0.02mL injection prefilled pen
ft92. BYETTA 10micrograms/0.04mL injection prefilled pen
ft93. BYDUREON 2mg powder and solvent for suspension for injection
ft94. BYDUREON 2mg powder+solvent for susp for inj prefilled pen
ft95. EXENATIDE 2mg powder+solvent for susp for inj prefilled pen
ft9x. EXENATIDE 2mg powder+solvent for suspension for injection
ft9y. EXENATIDE 10micrograms/0.04mL injection prefilled pen
ft9z. EXENATIDE 5micrograms/0.02mL injection prefilled pen
fta.. VILDAGLIPTIN
fta1. GALVUS 50mg tablets
ftaZ. VILDAGLIPTIN 50mg tablets
ftb.. METFORMIN+VILDAGLIPTIN
ftb1. EUCREAS 50mg/850mg tablets
ftb2. EUCREAS 50mg/1000mg tablets
ftby. VILDAGLIPTIN/METFORMIN 50mg/1000mg tablets
ftbz. VILDAGLIPTIN/METFORMIN 50mg/850mg tablets
ftc.. LIRAGLUTIDE
ftc1. VICTOZA 6mg/mL solution for injection prefilled pen 3mL
ftc2. LIRAGLUTIDE 6mg/mL solution for injection prefilled pen
ftd.. SAXAGLIPTIN
ftd1. ONGLYZA 5mg tablets
ftd2. ONGLYZA 2.5mg tablets
ftdy. SAXAGLIPTIN 2.5mg tablets
ftdz. SAXAGLIPTIN 5mg tablets
fte.. METFORMIN+ SITAGLIPTIN
fte1. JANUMET 50mg/1000mg tablets
ftez. SITAGLIPTIN/METFORMIN HYDROCHLORIDE 50mg/1000mg tablets
ftf.. LINAGLIPTIN
ftf1. TRAJENTA 5mg tablets
ftf2. LINAGLIPTIN 5mg tablets
ftg.. METFORMIN+ LINAGLIPTIN
ftg1. JENTADUETO 2.5mg/850mg tablets
ftg2. LINAGLIPTIN/METFORMIN HYDROCHLORIDE 2.5mg/850mg tablets
ftg3. JENTADUETO 2.5mg/1000mg tablets
ftg4. LINAGLIPTIN/METFORMIN HYDROCHLORIDE 2.5mg/1000mg tablets
fth.. DAPAGLIFLOZIN
fth1. FORXIGA 5mg tablets
fth2. FORXIGA 10mg tablets
fth3. DAPAGLIFLOZIN 5mg tablets
fth4. DAPAGLIFLOZIN 10mg tablets
fti.. METFORMIN+ SAXAGLIPTIN
fti1. KOMBOGLYZE 2.5mg/850mg tablets
fti2. SAXAGLIPTIN/METFORMIN HYDROCHLORIDE 2.5mg/850mg tablets
fti3. KOMBOGLYZE 2.5mg/1000mg tablets
fti4. SAXAGLIPTIN/METFORMIN HYDROCHLORIDE 2.5mg/1000mg tablets
ftj.. LIXISENATIDE
ftj1. LYXUMIA 10micrograms/0.2mL soln for inj prefilled pen 3mL
ftj2. LIXISENATIDE 10micrograms/0.2mL soln for injection pen 3mL
ftj3. LYXUMIA 20micrograms/0.2mL soln for inj prefilled pen 3mL
ftj4. LIXISENATIDE 20micrograms/0.2mL soln for injection pen 3mL
ftj5. LYXUMIA 10mcg/0.2mL+20mcg/0.2mL soln inj prefilled pens 3mL
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ftj6. LIXISENATIDE 10mcg/0.2mL+20mcg/0.2mL soln for inj pens 3mL
ftk.. ALOGLIPTIN
ftk1. VIPIDIA 6.25mg tablets
ftk2. ALOGLIPTIN 6.25mg tablets
ftk3. VIPIDIA 12.5mg tablets
ftk4. ALOGLIPTIN 12.5mg tablets
ftk5. VIPIDIA 25mg tablets
ftk6. ALOGLIPTIN 25mg tablets
ftl.. METFORMIN+ALOGLIPTIN
ftl1. VIPDOMET 12.5mg/1000mg tablets
ftl2. ALOGLIPTIN+METFORMIN HYDROCHLORIDE 12.5mg/1000mg tablets
ftm.. METFORMIN+DAPAGLIFLOZIN
ftm1. XIGDUO 5mg/850mg tablets
ftm2. DAPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 5mg/850mg tablets
ftm3. XIGDUO 5mg/1000mg tablets
ftm4. DAPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 5mg/1000mg tablets
ftn.. CANAGLIFLOZIN
ftn1. INVOKANA 100mg tablets
ftn2. CANAGLIFLOZIN 100mg tablets
ftn3. INVOKANA 300mg tablets
ftn4. CANAGLIFLOZIN 300mg tablets
fto.. EMPAGLIFLOZIN
fto1. JARDIANCE 10mg tablets
fto2. EMPAGLIFLOZIN 10mg tablets
fto3. JARDIANCE 25mg tablets
fto4. EMPAGLIFLOZIN 25mg tablets
ftp.. METFORMIN+CANAGLIFLOZIN
ftp1. VOKANAMET 50mg/850mg tablets
ftp2. CANAGLIFLOZIN+METFORMIN HYDROCHLORIDE 50mg/850mg tablets
ftp3. VOKANAMET 50mg/1000mg tablets
ftp4. CANAGLIFLOZIN+METFORMIN HYDROCHLORIDE 50mg/1000mg tablets
ftq.. DULAGLUTIDE
ftq1. TRULICITY 750 micrograms/0.5mL soln for injection p/f pen
ftq2. DULAGLUTIDE 750 micrograms/0.5mL soln for injection p/f pen
ftq3. TRULICITY 1.5mg/0.5mL solution for injection prefilled pen
ftq4. DULAGLUTIDE 1.5mg/0.5mL soln for injection prefilled pen
ftq5. TRULICITY 750 micrograms/0.5mL soln for inj prefilled syringe
ftq6. DULAGLUTIDE 750 micrograms/0.5mL solution for injection pfs
ftq7. TRULICITY 1.5mg/0.5mL soln for injection prefilled syringe
ftq8. DULAGLUTIDE 1.5mg/0.5mL soln for injection prefilled syringe
ftr.. METFORMIN+EMPAGLIFLOZIN
ftr1. SYNJARDY 5mg/850mg tablets
ftr2. EMPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 5mg/850mg tablets
ftr3. SYNJARDY 5mg/1000mg tablets
ftr4. EMPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 5mg/1000mg tablets
ftr5. SYNJARDY 12.5mg/850mg tablets
ftr6. EMPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 12.5mg/850mg tablets
ftr7. SYNJARDY 12.5mg/1000mg tablets
ftr8. EMPAGLIFLOZIN+METFORMIN HYDROCHLORIDE 12.5mg/1000mg tablets
fts.. ALBIGLUTIDE
fts1. EPERZAN 30mg powder+solvent for solution for injection
fts2. ALBIGLUTIDE 30mg powder+solvent for solution for injection
puh.. BLOOD GLUCOSE TESTING STRIPS..
puh1. ∗BM TEST-1-44 strip x50. BM TEST-1-44 blood glucose testing strip x50.
puh2. ∗DEXTROSTIX strip x50. DEXTROSTIX blood glucose testing strip x50.
puh3. ∗GLUCOSTIX strip x50. GLUCOSTIX blood glucose testing strip x50.
puh4. ∗HYPOGUARD GA strip x50. HYPOGUARD GA blood glucose testing strip x50.
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puh5. ∗EXACTECH strip x50. EXACTECH blood glucose testing strip x50.
puh6. ∗HYPOGUARD SUPREME strip x50. HYPOGUARD SUPREME blood glucose testing strip x50.
puh7. ∗BM ACCUTEST strip x50. BM ACCUTEST blood glucose testing strip x50.
puh8. ∗GLUCOSTIX strip x25. GLUCOSTIX blood glucose testing strip x25.
puh9. ∗ONE TOUCH glucose test strip. ONE TOUCH blood glucose testing strip.
puhA. ∗BM-TEST-GP strip x100. BM-TEST-GP blood glucose testing strip x100.
puhB. ∗BM-HOPITEST strip x50. BM-HOPITEST blood glucose testing strip x50.
puhC. ∗MEDI-TEST GLYCAEMIE P strip. MEDI-TEST GLYCAEMIE P blood glucose testing strip.
puhD. ∗MEDI-TEST GLYCAEMIE F strip. MEDI-TEST GLYCAEMIE F blood glucose testing strip.
puhE. ∗MEDI-TEST GLYCAEMIE C strip. MEDI-TEST GLYCAEMIE C blood glucose testing strip.
puhF. ∗MEDISENSE G2 test strip. MEDISENSE G2 blood glucose testing strip.
puhG. ∗GLUCOTIDE test strip. GLUCOTIDE blood glucose testing strip.
puhH. ∗GLUCOMETER ESPRIT test disc. GLUCOMETER ESPRIT blood glucose test sensor disc.
puhI. ∗GLUCOTREND test strips. GLUCOTREND blood glucose testing strips.
puhJ. ∗POCKETSCAN test strip. POCKETSCAN blood glucose testing strip.
puhK. ∗MEDISENSE OPTIUM electrode. MEDISENSE OPTIUM blood glucose testing electrode.
puhL. ∗HYPOGARD SUPRME SPCT strp x50. HYPOGUARD SUPREME SPECTRUM blood glucose testing strip x50.
puhM. MEDISENSE OPTIUM PLS electrode. MEDISENSE OPTIUM PLUS blood glucose testing electrode.
puhN. ∗ON-CALL PLUS strip. ON-CALL PLUS blood glucose testing strip.
puhO. BREEZE 2 test disc. BREEZE 2 blood glucose test sensor disc.
puhP. BETACHEK G5 test strip. BETACHEK G5 blood glucose testing strip.
puhQ. FREESTYLE LITE testing strip. FREESTYLE LITE blood glucose testing strip.
puhR. ∗BIONIME RIGHTEST GS300 strip. BIONIME RIGHTEST GS300 blood glucose testing strip.
puhS. ∗MICRODOT test strip. MICRODOT blood glucose testing strip.
puhS. MICRODOT test strip. MICRODOT blood glucose testing strip.
puhT. GLUCOMEN LX SENSOR strip. GLUCOMEN LX SENSOR blood glucose testing strip.
puhU. ONE TOUCH VITA test strip. ONE TOUCH VITA blood glucose testing strip.
puhV. WAVESENSE JAZZ test strip. WAVESENSE JAZZ blood glucose testing strip.
puhW. BETACHEK VISUAL test strip. BETACHEK VISUAL blood glucose testing strip.
puhX. COSYLAB S7 glucose test strip. COSYLAB S7 blood glucose testing strip.
puhY. CARESENS N testing strip. CARESENS N blood glucose testing strip.
puhZ. PURA blood glucose test strip. PURA blood glucose testing strip.
puha. FINETOUCH blood gluc test tip. FINETOUCH blood glucose testing tip.
puhb. GLUCOMEN GM test strip. GLUCOMEN GM blood glucose testing strip.
puhc. CLEVER CHEK test strip. CLEVER CHEK blood glucose testing strip.
puhc. ∗CLEVER CHEK test strip. CLEVER CHEK blood glucose testing strip.
puhd. TRUETEST test strip. TRUETEST blood glucose testing strip.
puhe. ACCU-CHEK MOBILE test cassette. ACCU-CHEK MOBILE blood glucose testing cassette.
puhf. ∗BIOCARE GLUCOSE VT strip. BIOCARE GLUCOSE VT blood glucose testing strip.
puhg. ∗SMARTSTRIP blood glucose test. SMARTSTRIP blood glucose testing strip.
puhh. GLUCOMEN SENSOR test strip. GLUCOMEN SENSOR blood glucose testing strip.
puhi. ∗GLUCOTREND PLUS test strips. GLUCOTREND PLUS blood glucose testing strips.
puhj. ADVANTAGE II testing strip. ADVANTAGE II blood glucose testing strip.
puhk. ∗PRESTIGE SMART SYSTEM strip. PRESTIGE SMART SYSTEM blood glucose testing strip.
puhl. ACTIVE glucose testing strip. ACTIVE blood glucose testing strip.
puhm. MEDISENSE SOFT-SENSE strip. MEDISENSE SOFT-SENSE blood glucose testing strip.
puhn. GLUCOFLEX-R strip. GLUCOFLEX-R blood glucose testing strip.
puhp. ONE TOUCH ULTRA strip. ONE TOUCH ULTRA blood glucose testing strip.
puhq. FREESTYLE testing strip. FREESTYLE blood glucose testing strip.
puhr. COMPACT test strip. COMPACT blood glucose testing strip.
puhs. ASCENSIA AUTODISC test disc. ASCENSIA AUTODISC blood glucose test sensor disc.
puhs. ∗ASCENSIA AUTODISC test disc. ASCENSIA AUTODISC blood glucose test sensor disc.
puht. ASCENSIA MICROFILL test strip. ASCENSIA MICROFILL blood glucose testing strip.
puhu. TRUETRACK SMART SYSTEM strip. TRUETRACK SMART SYSTEM blood glucose testing strip.
puhv. ∗SENOVA blood gluc test strip. SENOVA blood glucose testing strip.
puhw. SENSOCARD test strip. SENSOCARD blood glucose testing strip.
puhx. AVIVA blood glucose test strip. AVIVA blood glucose testing strip.
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puhy. GLUCOMEN VISIO SENSOR strip. GLUCOMEN VISIO SENSOR blood glucose testing strip.
puhz. ∗ON-CALL NOW blood glcose strp. ON-CALL NOW blood glucose testing strip.
pui.. BLOOD GLUCOSE METERS..
pui1. ∗ACCUTREND blood glucose meter..
pui2. ∗ACCUTREND ALPHA meter. ACCUTREND ALPHA blood glucose meter.
pui3. ∗ACCUTREND MINI meter. ACCUTREND MINI blood glucose meter.
pui4. ∗EXACTECH blood glucose meter..
pui5. EXACTECH PEN meter. EXACTECH PEN blood glucose meter.
pui6. MEDISENSE COMPANION 2 meter. MEDISENSE COMPANION 2 blood glucose meter.
pui7. MEDISENSE PEN 2 meter. MEDISENSE PEN 2 blood glucose meter.
pui8. ∗GLUCOMETER 4 meter. GLUCOMETER 4 blood glucose meter.
pui9. GLUCOMETER GX meter. GLUCOMETER GX blood glucose meter.
puiA. GLYCOTRONIC C meter. GLYCOTRONIC C blood glucose meter.
puiB. ∗HYPOCOUNT GA meter. HYPOCOUNT GA blood glucose meter.
puiC. HYPOCOUNT SUPREME meter. HYPOCOUNT SUPREME blood glucose meter.
puiD. ∗ONE TOUCH blood glucose meter..
puiE. ∗ONE TOUCH II meter. ONE TOUCH II blood glucose meter.
puiF. ∗REFLOLUX S meter. REFLOLUX S blood glucose meter.
puiG. ∗ONE TOUCH PROFILE meter. ONE TOUCH PROFILE blood glucose meter.
puiH. ∗GLUCOTREND blood glucose metr. GLUCOTREND blood glucose meter.
puiI. ∗ESPRIT GLUCOMETER. ESPRIT GLUCOMETER blood glucose meter.
puiJ. SAKURA-GL II meter. SAKURA-GL II blood glucose meter.
puiK. GLUCOTREND PREMIUM meter. GLUCOTREND PREMIUM blood glucose meter.
puiL. ∗SUPREME PETIT meter. SUPREME PETIT blood glucose meter.
puiM. ∗POCKETSCAN blood glucose mtr. POCKETSCAN blood glucose meter.
puiN. MEDISENSE OPTIUM meter. MEDISENSE OPTIUM blood glucose meter.
puiO. ∗SUPREME EXTRA meter. SUPREME EXTRA blood glucose meter.
puiP. ∗SUPREME PLUS meter. SUPREME PLUS blood glucose meter.
puiQ. GLUCOMETER ESPRIT 2 meter. GLUCOMETER ESPRIT 2 blood glucose meter.
puiR. ∗ACCU-CHEK ACTIVE meter. ACCU-CHEK ACTIVE blood glucose meter.
puiS. ∗ACCU-CHEK ADVANTAGE meter. ACCU-CHEK ADVANTAGE blood glucose meter.
puiT. SOFT-SENSE blood glucose meter..
puiU. ∗PRESTIGE SMART SYSTM LX meter. PRESTIGE SMART SYSTEM LX blood glucose meter.
puiV. ∗PRESTIGE SMART SYSTEM QX mter. PRESTIGE SMART SYSTEM QX blood glucose meter.
puiW. ∗ONE TOUCH ULTRA meter. ONE TOUCH ULTRA blood glucose meter.
puiX. ∗ACCU-CHEK COMPACT meter. ACCU-CHEK COMPACT blood glucose meter.
puiY. FREESTYLE blood glucose meter..
puiZ. ASCENSIA BREEZE glucose meter. ASCENSIA BREEZE blood glucose meter.
puia. ONE TOUCH ULTRASMART meter. ONE TOUCH ULTRASMART blood glucose meter.
puib. ASCENSIA CONTOUR meter. ASCENSIA CONTOUR blood glucose meter.
puic. FREESTYLE MINI glucose meter. FREESTYLE MINI blood glucose meter.
puid. TRUETRACK SMART SYSTEM meter. TRUETRACK SMART SYSTEM blood glucose meter.
puie. ∗SENOVA blood glucose meter..
puif. OPTIUM XCEED glucose meter. OPTIUM XCEED blood glucose meter.
puig. ACCU-CHEK COMPACT PLUS meter. ACCU-CHEK COMPACT PLUS blood glucose meter.
puih. SENSOCARD PLUS meter. SENSOCARD PLUS blood glucose meter.
puii. ON-CALL NOW blood glucse meter. ON-CALL NOW blood glucose meter.
puij. GLUCOMEN VISIO meter. GLUCOMEN VISIO blood glucose meter.
puik. BETACHEK G5 meter. BETACHEK G5 blood glucose meter.
puil. BREEZE 2 blood glucose meter..
puim. FREESTYLE LITE meter. FREESTYLE LITE blood glucose meter.
puin. FREESTYLE FREEDOM LITE meter. FREESTYLE FREEDOM LITE blood glucose meter.
puio. ∗BIONIME RIGHTEST GM300 meter. BIONIME RIGHTEST GM300 blood glucose meter.
puip. ∗MICRODOT blood glucose meter..
puip. MICRODOT blood glucose meter..
puiq. GLUCOMEN LX blood glucse meter. GLUCOMEN LX blood glucose meter.
puir. ONE TOUCH VITA glucose meter. ONE TOUCH VITA blood glucose meter.
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puis. WAVESENSE JAZZ glucose meter. WAVESENSE JAZZ blood glucose meter.
puit. ACCU-CHEK AVIVA NANO meter. ACCU-CHEK AVIVA NANO blood glucose meter.
puiu. COSYLAB S7 blood glucose meter..
puiv. CARESENS N blood glucose meter..
puiw. PURA blood glucose meter..
puix. ACCU-CHEK MOBILE meter. ACCU-CHEK MOBILE blood glucose meter.
puiy. TRUERESULT blood glucose meter..
puiz. TRUE2GO blood glucose meter..
puk.. BLOOD GLUCOSE TESTING KIT..
puk1. ∗GLUCOTREND SOFT TEST SYSTEM..
puk2. ∗GLUCOTREND-2 SOFT TEST SYSTEM..
puk3. AVIVA blood glucose test kit..
pun.. BLOOD KETONE TESTING STRIPS..
pun1. ∗OPTIUM blood ketone test strp. MEDISENSE OPTIUM blood ketone test strip.
pun2. OPTIUM blood ketone strips. OPTIUM blood ketone test strips.
pun3. GLUCOMEN LX blood ketone strip. GLUCOMEN LX blood ketone test strips.
puq.. BLOOD GLUCOSE METERS (2)..
puq1. CLEVER CHEK meter. CLEVER CHEK blood glucose meter.
puq2. CLEVER CHEK VOICE meter. CLEVER CHEK VOICE blood glucose meter.
puq3. FINETOUCH blood glucose meter..
puq4. GLUCOMEN GM meter. GLUCOMEN GM blood glucose meter.
puq5. GLUCORX blood glucose meter..
puq6. IME-DC blood glucose meter..
puq7. OMNITEST 3 blood glucose meter..
puq8. ONETOUCH VERIOPRO meter. ONETOUCH VERIOPRO blood glucose meter.
puq9. ON-CALL ADVANCED meter. ON-CALL ADVANCED blood glucose meter.
puqA. GLUCORX NEXUS meter. GLUCORX NEXUS blood glucose meter.
puqB. ONETOUCH ULTRA 2 meter. ONETOUCH ULTRA 2 blood glucose meter.
puqC. ONETOUCH ULTRAEASY meter. ONETOUCH ULTRAEASY blood glucose meter.
puqD. GLUCOMEN LX PLUS meter. GLUCOMEN LX PLUS blood glucose and ketone meter.
puqE. SUPERCHECK 2 meter. SUPERCHECK 2 blood glucose meter.
puqF. GLUCOLAB blood glucose meter..
puqG. ELEMENT blood glucose meter..
puqH. BGSTAR blood glucose meter..
puqI. CONTOUR XT blood glucose meter..
puqJ. MENDOR DISCREET meter. MENDOR DISCREET blood glucose meter.
puqK. TRUERESULT TWIST meter. TRUERESULT TWIST blood glucose meter.
puqL. SD CODEFREE meter. SD CODEFREE blood glucose meter.
puqM. TRUEYOU MINI meter. TRUEYOU MINI blood glucose meter.
puqN. MYLIFE UNIO meter. MYLIFE UNIO blood glucose meter.
puqO. ICARE ADVANCED meter. ICARE ADVANCED blood glucose meter.
puqP. AUTOSENSE blood glucose meter..
puqQ. AUTOSENSE VOICE meter. AUTOSENSE VOICE blood glucose meter.
puqR. SURESIGN RESURE meter. SURESIGN RESURE blood glucose meter.
puqS. TEE2 blood glucose meter..
puqT. CONTOUR TS blood glucose meter..
puqU. DARIO blood glucose meter..
puqV. GLUNEO blood glucose meter..
puqW. GLUCOMEN AREO meter. GLUCOMEN AREO blood glucose meter.
puqX. SUPERCHECK PLUS meter. SUPERCHECK PLUS blood glucose meter.
puqY. ONETOUCH SELECT PLUS meter. ONETOUCH SELECT PLUS blood glucose meter.
puqZ. ADVOCATE REDI-CODE+ meter. ADVOCATE REDI-CODE+ blood glucose meter.
puqa. ACCU-CHEK PERFORMA meter. ACCU-CHEK PERFORMA blood glucose meter.
puqb. IHEALTH ALIGN meter. IHEALTH ALIGN blood glucose meter.
puqc. IHEALTH GLUCO meter. IHEALTH GLUCO blood glucose meter.
puqd. GLUCOZEN AUTO meter. GLUCOZEN AUTO blood glucose meter.
puqe. BETACHEK C50 meter. BETACHEK C50 blood glucose meter.
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pur.. BLOOD GLUCOSE TEST STRIPS (2). BLOOD GLUCOSE TESTING STRIPS (2).
pur1. GLUCORX test strip. GLUCORX blood glucose testing strip.
pur2. IME-DC test strip. IME-DC blood glucose testing strip.
pur3. OMNITEST 3 glucose test strip. OMNITEST 3 blood glucose testing strip.
pur4. ONETOUCH VERIO test strip. ONETOUCH VERIO blood glucose testing strip.
pur5. ON-CALL ADVANCED test strip. ON-CALL ADVANCED blood glucose testing strip.
pur6. GLUCORX NEXUS test strip. GLUCORX NEXUS blood glucose testing strip.
pur7. SUPERCHECK 2 test strip. SUPERCHECK 2 blood glucose testing strip.
pur8. GLUCOLAB test strip. GLUCOLAB blood glucose testing strip.
pur9. ELEMENT test strip. ELEMENT blood glucose testing strip.
purA. BGSTAR test strip. BGSTAR blood glucose testing strip.
purB. CONTOUR NEXT test strip. CONTOUR NEXT blood glucose testing strip.
purC. MENDOR DSCREET test strip cart. MENDOR DISCREET blood glucose testing strip cartridge.
purD. GLUCODOCK test strip. GLUCODOCK blood glucose testing strip.
purE. MEDITOUCH test strip. MEDITOUCH blood glucose testing strip.
purF. TRUEONE test strip+meter. TRUEONE blood glucose testing strip with built-in meter.
purG. TRUERESULT test strip. TRUERESULT blood glucose testing strip.
purH. SD CODEFREE test strip. SD CODEFREE blood glucose testing strip.
purI. TRUEYOU testing strip. TRUEYOU blood glucose testing strip.
purJ. WAVESENSE JAZZ duo pack strip. WAVESENSE JAZZ duo pack blood glucose testing strip.
purK. MYLIFE UNIO testing strip. MYLIFE UNIO blood glucose testing strip.
purL. ICARE ADVANCED SOLO test strip. ICARE ADVANCED SOLO blood glucose testing strip.
purM. AUTOSENSE testing strip. AUTOSENSE blood glucose testing strip.
purN. SURESIGN RESURE testing strip. SURESIGN RESURE blood glucose testing strip.
purO. TEE2 blood glucose test strip. TEE2 blood glucose testing strip.
purP. CONTOUR TS testing strip. CONTOUR TS blood glucose testing strip.
purQ. DARIO blood glucose test strip. DARIO blood glucose testing strip.
purR. GLUNEO test strip. GLUNEO blood glucose testing strip.
purS. GLUCOMEN AREO SENSOR strip. GLUCOMEN AREO SENSOR blood glucose testing strip.
purT. SUPERCHECK PLUS test strip. SUPERCHECK PLUS blood glucose testing strip.
purU. ONETOUCH SELECT PLUS strip. ONETOUCH SELECT PLUS blood glucose testing strip.
purV. ADVOCATE REDI-CODE+ test strip. ADVOCATE REDI-CODE+ blood glucose testing strip.
purW. ACCU-CHEK PERFORMA test strip. ACCU-CHEK PERFORMA blood glucose testing strip.
purX. IHEALTH test strip. IHEALTH blood glucose testing strip.
purY. GLUCOZEN AUTO test strip. GLUCOZEN AUTO blood glucose testing strip.
purZ. BETACHEK C50 test cassette. BETACHEK C50 blood glucose testing cassette.
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